Physiopathological, diagnostic and therapeutic impacts of chromosomal translocations in hematological malignancies;Translocations récurrentes en onco-hématologie: Physiopathologie, intérêt clinique et thérapeutique

Bulletin du Cancer

Volumn 98, Issue 12, 2011, Pages 1403-1418

  Ravinet, Aurélie ^a   Belille, Mathilde Gay ^b   Lemal, Richard ^a   Veronese, Lauren ^b   Bay, Jacques Olivier ^a   Prie, Nolwen ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Chimeric gene; Proto oncogene; Targeted therapy; Transcriptional activation; Translocation

Indexed keywords

CHIMERIC PROTEIN;

CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; DOWN REGULATION; FUSION GENE; GENE ACTIVATION; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETIC REGULATION; GENOMICS; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMOGENESIS; PATHOPHYSIOLOGY; PROTO ONCOGENE; REVIEW;

EID: 84855238670     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1509     Document Type: Review

References (59)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
3. Bartram CR, De Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80. (Pubitemid 14232360)
4. de Klein A, Van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronicmyelocytic leukaemia. Nature 1982;300:765-7. (Pubitemid 13224358)
5. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, BCR, on chromosome 22. Cell 1984;36:93-9. (Pubitemid 14155374)
6. Gisselbrecht S. Oncogenes and leukemia: history and perspectives. Med Sci 2003;19:201-10.
7. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994;372:143-9. (Pubitemid 24347832)
8. Nguyen Khac F, Bernard OA. Chromosomal translocations in human malignant hematopoiesis. Structural and functional consequences. Pathol Biol 2003;51:382-9. (Pubitemid 37064652)
9. Berger R. Human cytogenetics. From 1956 to 2006. Pathol Biol 2007;55:1-12.
10. Fröhling S, Döhner H. Chromosomal abnormalities in cancer. N Engl J Med 2008;359:722-34.
11. Pasternak G, Hochhaus A, Schultheis B, et al. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol 1998;124:643-60. (Pubitemid 29003297)
12. Carron C, Lopez R, Cormier F. Implication of TEL-derived proteins in oncogenesis. Hématologie 1999;5:143-52.
13. Jousset C, Carron C, Boureux B, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 1997;16:69-82. (Pubitemid 27032851)
14. Link KA, Chou FS, Mulloy JC. Core binding factor at the crossroads: determining the fate of the HSC. J Cell Physiol 2010;222:50-6.
15. Hart SM, Foroni L. Core binding factor genes and human leukemia. Haematologica 2002;87:1307-23. (Pubitemid 36005305)
16. Cai Z, De Bruijn M, Ma X, et al. Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. Immunity 2000;13:423-31.
17. Huret JL, Dessen P, Bernheim A. An Internet database on genetics in oncology. Oncogene 2003;22:1907.
18. Liu H, Cheng EHY, Hsieh JJD. MLL fusions: pathways to leukemia. Cancer Biol Ther 2009;8:1204-11.
19. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33. (Pubitemid 350006257)
20. Hosokawa Y. Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma. Apoptosis 2005;10:25-34. (Pubitemid 40558113)
21. Bernheim A, Berger R, Lenoir G. Translocations t(2;8) and t(8;22) in continuous cell lines of African Burkitt's lymphoma. C R Seances Acad Sci D 1980;291:237-9. (Pubitemid 11200878)
22. Lenoir GM, Preud'homme JL, Bernheim A, et al. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature 1982;298:474-6. (Pubitemid 12095628)
23. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982;79:7824-7. (Pubitemid 13182471)
24. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 1982;79:7837-41. (Pubitemid 13182474)
25. Delsol G. Molecular abnormalities in lymphomas. Bull Cancer 2010;97:1347-64.
26. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002;21:3295-313. (Pubitemid 34587705)
27. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001;15:1495-504. (Pubitemid 32994666)
28. Künstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002;22:1513-25. (Pubitemid 34150787)
29. Raffeld M, Jaffe ES. Bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 1991;78:259-63.
30. Tsujimoto Y, Gorham J, Cossman J, et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-3. (Pubitemid 16222379)
31. Levy ER, Parganas E, Morishita K, et al. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 1994;83:1348-54. (Pubitemid 24062858)
32. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 2009;353-61.
33. Bernard O. Mechanisms of leucemogenesis. Bull Cancer 2010;97:1381-8.
34. Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?. Leukemia 2007;21:622- 6.
35. Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401- 23.
36. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
37. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood 2010;116:3758-65.
38. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
39. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37. (Pubitemid 43990609)
40. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005;23:6306-15. (Pubitemid 46218840)
41. Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009;21(suppl. 1):S43-6.
42. Martens JHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 2010;584:2662-9.
43. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 2006;514:156-61.
44. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
45. Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009;16:84-91.
46. Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. Curr Opin Hematol 2009;16:92-7.
47. Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010;22:646-55.
48. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
49. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40. (Pubitemid 32056501)
50. Janz S, Potter M, Rabkin CS. Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer 2003;36:211-23. (Pubitemid 36158194)
51. Liu Y, Hernandez AM, Shibata D, et al. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 1994;91:8910-4.
52. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 2002;99:8242-7. (Pubitemid 34651037)
53. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. (Pubitemid 26358996)
54. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-43. (Pubitemid 41039124)
55. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002;100:585-93. (Pubitemid 34761123)
56. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell 2002;1:417-20. (Pubitemid 41039122)
57. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998;12:845-59. (Pubitemid 28287205)
58. Linggi B, Müller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002;8:743-50. (Pubitemid 34778729)
59. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;4:327-40.